Since then, public and private research has been applied continually to improve canola value. This research includes traditional science and biotechnology, including genetic modification. The combination of these methodologies and a relentless focus on innovation is creating profitability for canola farmers and economic growth for Canada.
Canola provides the most value to Canadian farmers of any crop. In 2010, cash receipts from canola were $5.6 billion. The 2010 crop produced 11.9 million tonnes of canola on 16.1 million acres of land, which is up from the 2006 numbers of 9.1 tonnes on 13 million acres of land. Canola generates $14 billion in economic activity in Canada and creates 216,000 jobs. This success can be attributed in no small part to biotechnology innovation.
The committee has asked for input on regulatory and policy issues that can encourage biotechnology innovation in agriculture.
To start with, we have to ensure that our regulatory system continues to be based on science. Technology companies are investing millions in research and development to bring new innovations to market. To do so, they need to have confidence that the regulatory framework for these products is predictable and is based on sound science. This is also very important in international markets. Canada is an exporting nation. A total of 80% to 90% of our canola production is exported. We rely on science-based regulatory systems around the world for predictable access to those markets. When decisions on market access are based on political calculations, these markets can close. So our first recommendation for your report is that the committee underscore the importance of science-based regulation. Canada should also be a strong voice internationally on this point.
As a major exporter of agriculture products, we have a lot to lose from the imposition of trade barriers. Ensuring that regulatory and policy decisions are based on science has to be a foundation principle of international trade. This is our goal in the current negotiations between Canada and the European Community on a trade and economic agreement. Canada and Europe both have rigorous processes for approving agricultural products based on genetic modification, but they differ in one important respect. In Canada, the product is approved if regulators, after a thorough safety assessment, conclude that it is safe. In Europe, there's basically a two-stage process. The European Food Safety Authority conducts a science-based safety assessment, very similar to Canada's, and issues an opinion. But then the application goes to a political level where it has to be approved by a committee of member states. This second part of the process causes considerable delay, and decision-making is not based on any clear criteria.
We are asking for this process to be predictable, timely, and science-based. To be clear, this does not involve any change in regulatory standards or a reduction in human or safety standards.
When it comes to the approval process for genetically modified materials, the timeliness of regulatory decision-making is important. Seed developers apply for approval in all major markets before commercializing a new GM trait. In most markets, a science-based safety assessment process should take 18 months to two years. If all major markets undertake these assessments and make decisions in this period of time, the number of unapproved events, which can disrupt trade, would be reduced.
GM is not a safety issue. The GM traits being used in canola today have been approved through rigorous regulatory processes by numerous science-based regulatory agencies, and 15 years of biotechnology in Canada have shown it to be safe. So when GM regulation is used to block access to markets, it's simply a non-tariff trade barrier.
We also ask the committee to make a strong recommendation that Canada and other major grain-trading nations develop low-level presence policies with respect to GM materials. Today the number of GM products being grown, and the acreage seeded with them, is growing quickly, and in many parts of the world. We have seen circumstances recently when GM materials approved in one or more countries, but not in the country importing the grain, have disrupted trade, causing significant economic disruption for farmers, grain handlers, and end-users. In these circumstances it is likely that this disruption is unnecessary, since the product has been deemed safe through safety assessment, is not being intentionally imported, and is at very low levels. These events are likely to be more frequent.
The solution dealing with trade issues involving GM products is the development of global policies and approaches to risk management and low-level presence. This can include the synchronization of GM approvals in all markets, mutual recognition where the regulatory authority in one country relies on the science-based review done by another, and development of low-level presence policies.
We urge the committee to recommend that Canada introduce a low-level presence policy to its domestic regulation and that our policy and regulatory officials lead discussions with their international counterparts to implement common standards for low-level presence internationally.
Finally, we urge the committee to make a recommendation in favour of continued federal investment in research. All around us countries are investing in agriculture innovation to improve their competitiveness internationally. Public and private research tends to have different objectives and timelines, but both have an important role to play. Agriculture Canada has played a monumental role in the success of Canadian agriculture through its research program, and will continue to be valuable in the future.
I thank the committee and look forward to questions.